Browse Articles

Escherichia coli engineered to display cytokines destroy hard-to-treat tumors by boosting the activity of local native and adoptive immune effector cells.

Bacteria expressing an anti-tumor cytokine act as a potent cancer immunotherapy.

The FDA’s approval of the first genetically modified T cell therapy for treating a rare sarcoma is paving the way for next-generation therapies that tackle other types of solid tumors.

Long, chemically modified pegRNAs are rapidly synthesized using an optimized splint ligation approach.

ProteinGenerator simultaneously generates protein sequences and structures using sequence space diffusion.

Prime editing efficiency is enhanced using a mutated reverse transcriptase and addition of deoxynucleosides.

Redesigning mRNA with chemo-topological strategies improves its stability and translation efficiency, paving the way for more effective mRNA therapeutics.

Bacteria, fungi and plants can be grown and engineered to remove plastics, chemicals and pollutants from contaminated soil and water.

Unsupervised analysis of single-cell RNA-sequencing data across cell types and individuals predicts disease severity.

SPLASH2 speeds up analysis of sequence variation in massive datasets.

mRNA cap designs boost translation >10-fold, with potential benefits for RNA therapies.

λ exonuclease (λExo) binds 5′-phosphorylated single-stranded DNA (pDNA) at complementary regions on double-stranded DNA and DNA–RNA duplexes under ambient conditions without a PAM-like motif. In the presence of Mg²⁺, λExo then digests the pDNA into nucleotides.

A differentiation method informed by developmental biology converts human pluripotent stem cells to engraftable hematopoietic stem and progenitor cells without the use of transgenes.

A λ exonuclease system exhibits protospacer-adjacent motif-independent DNA-binding specificity, enabling diagnostic and imaging applications.

Genome editing tools are developed through large-scale characterization of bacterial retrons.